Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.
about
A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis.MR Imaging Biomarkers in Oncology Clinical TrialsModified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.Development of a Multiparametric Voxel-Based Magnetic Resonance Imaging Biomarker for Early Cancer Therapeutic Response Assessment.An Update on the Approach to the Imaging of Brain Tumors.Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials.Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma.Survival prediction based on qualitative MRI diffusion signature in patients with recurrent high grade glioma treated with bevacizumab.
P2860
Q27342179-39A48769-8ACB-4F46-AD08-52F97F88D3D7Q30364608-53C3702F-FABA-4A42-9359-9C1707778D02Q33586021-09E616BA-1541-449E-9043-AB2E31303C0BQ36275542-CF629017-0D59-43C6-B6C9-A8FA33C1A124Q36374577-BEF25B45-6ACE-4C8C-BABC-70762E05CB09Q37510450-81B88EF9-10B2-4E00-B03C-9FBCA9209B57Q39435280-DFC51D99-1014-4B87-B5B0-7417485CCF3FQ42702318-5C48F43D-4A16-4C0E-94D8-B9475E5607DEQ47161135-9166720F-CB91-4D1A-BF78-11ADF12DC9FAQ47436703-21DC0BB8-99BD-454B-8344-FC99179AA54DQ55035317-3F8D67F2-8F76-4E1C-8F2E-591B566A5F1B
P2860
Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Diffusion MRI quality control ...... apy in recurrent glioblastoma.
@ast
Diffusion MRI quality control ...... apy in recurrent glioblastoma.
@en
type
label
Diffusion MRI quality control ...... apy in recurrent glioblastoma.
@ast
Diffusion MRI quality control ...... apy in recurrent glioblastoma.
@en
prefLabel
Diffusion MRI quality control ...... apy in recurrent glioblastoma.
@ast
Diffusion MRI quality control ...... apy in recurrent glioblastoma.
@en
P2093
P2860
P921
P356
P1476
Diffusion MRI quality control ...... rapy in recurrent glioblastoma
@en
P2093
A Gregory Sorensen
Benjamin M Ellingson
Davis C Woodworth
Eunhee Kim
Felix Bokstein
Helga Marques
Jerrold L Boxerman
Mark R Gilbert
Robert C McKinstry
T Linda Chi
P2860
P304
P356
10.3892/IJO.2015.2891
P577
2015-02-11T00:00:00Z